Long Noncoding RNA SNHG16 Silencing Inhibits the Aggressiveness of Gastric Cancer via Upregulation of microRNA-628-3p and Consequent Decrease of NRP1 [Retraction]

Pang, Weifeng; Zhai, Mingcui; Wang, Yue; Li, Zhiqiang

doi:10.2147/cmar.s341062

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e TIDE algorithm analysis showed that patients in the subtype 1 group showed considerably higher TIDE ratings than those in the subtype 2 group, indicating that patients in the subtype 2 group might respond better to immunotherapy. Other noncoding RNAs might be valuable in the prediction of the prognosis of glioma [45][46][47].…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Chen

Peng

Teng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Glioma is the most commonly occurring primary neuroepithelial neoplasm. Long noncoding RNAs (lncRNAs) are emerging as pivotal modulators of gene expression in the immune system and play critical roles in the growth, progression, and immune response of carcinomas. In this study, we performed univariate Cox regression analysis on survival data from TCGA and identified 20 prognostic lncRNAs. Moreover, we revealed that these prognosis-related lncRNAs (PRLnc) were dysregulated in glioma. Furthermore, we constructed a signature based on the expression levels of these prognosis-related lncRNAs based on 13 prognostic lncRNAs, including AGAP2-AS1, CYTOR, MIR155HG, LINC00634, HOTAIRM1, SNHG18, LINC01841, LINC01842, LINC01426, MIR9-3HG, TMEM220-AS1, LINC00641, LINC01270, and LINC01503. The Kaplan–Meier curves show that high-risk patients had a shorter survival time. Finally, the glioma samples were classified into 2 subgroups based on the median expression of prognosis-related lncRNAs in each sample. In summary, these findings suggest that PRLnc is associated with tumor-infiltrating immune cells in glioma and that subtype 2 patients may respond more positively to immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Chen

Peng

Teng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Furthermore, silencing SNHG16 effectively sensitized 5-Fu-resistant GC cells. Although previous studies have reported that SNHG16 was a gastric cancer cell-favorite molecule [31][32][33], our results for the first time demonstrated the roles of SNHG16 in 5-Fu-resistant gastric cancer. Given that lncRNAs function as competitive endogenous RNAs (ceRNA) of miRNAs by sponging them to suppress miRNA expressions, leading to recovery of the miRNA target gene expressions, to investigate the molecular mechanisms, we identified miR-506-3p, which has been reported to function as a tumor suppressive miRNA in multiple cancers [28][29][30], was a directly downstream target of SNHG16 in GC cells by luciferase assay.…”

Section: Discussioncontrasting

confidence: 60%

Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism

Ding

Gao²,

Zheng

et al. 2022

Cancer Metab

View full text Add to dashboard Cite

Background Gastric cancer (GC) is a commonly occurring human malignancy. The 5-fluorouracil (5-Fu) is a first-line anti-gastric cancer agent. However, a large number of GC patients developed 5-Fu resistance. Currently, the roles and molecular mechanisms of the lncRNA-SNHG16-modulated 5-Fu resistance in gastric cancer remain elusive. Methods Expressions of lncRNA, miRNA, and mRNA were detected by qRT-PCR and Western blot. RNA-RNA interaction was examined by RNA pull-down and luciferase assay. Cell viability and apoptosis rate under 5-Fu treatments were determined by MTT assay and Annexin V assay. The glycolysis rate of GC cells was evaluated by glucose uptake and ECAR. Results Here, we report that SNHG16 as well as PTBP1, which is an RNA-binding protein, are positively associated with 5-Fu resistance to gastric cancer. SNHG16 and PTBP1 were significantly upregulated in gastric tumors and cell lines. Silencing SNHG16 or PTBP1 effectively sensitized GC cells to 5-Fu. Furthermore, glucose metabolism was remarkedly elevated in 5-Fu-resistant GC cells. Under low glucose supply, 5-Fu-resistant cells displayed higher vulnerability than parental GC cells. Bioinformatic analysis and luciferase assay demonstrated that SNHG16 downregulated miR-506-3p by sponging it to form a ceRNA network. We identified PTBP1 as a direct target of miR-506-3p in GC cells. RNA-seq results unveiled that PTBP1 positively regulated expressions of multiple glycolysis enzymes, including GLUT1, HK2, and LDHA. Bioinformatic analysis illustrated the 3′UTRs of glycolysis enzymes contained multiple PTBP1 binding sites, which were further verified by RNA pull-down and RNA immunoprecipitation assays. Consequently, we demonstrated that PTBP1 upregulated the mRNAs of glycolysis enzymes via promoting their mRNA stabilities. Finally, in vivo xenograft experiments validated that blocking the SNHG16-mediated miR-506-3p-PTBP1 axis effectively limited 5-Fu-resistant GC cell originated-xenograft tumor growth under 5-Fu treatments. Conclusions Our study demonstrates molecular mechanisms of the SNHG16-mediated 5-Fu resistance of GC cells through modulating the miR-506-3p-PTBP1-glucose metabolism axis, presenting a promising approach for anti-chemoresistance therapy.

show abstract

“…Hence, patients had stable blood levels after daily oral low-dose apatinib with better efficacy than bevacizumab used alone once every 3 weeks. Apatinib not only inhibits tumor neovascularization [23] and suppresses glioma cell invasion but also may activate the GBM immune response to exert antitumor effects [24][25][26][27][28][29]. Common adverse effects of apatinib include hypertension, proteinuria, and hand-foot syndrome, most of which can be tolerated and some of which are controlled by adjusting antihypertensive medications.…”

Section: Discussionmentioning

confidence: 99%

Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas

Zhang

Gao

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To evaluate the efficacy, safety, and prognostic value of low-dose apatinib in combination with temozolomide in the treatment of primary or recurrent high-grade gliomas (HGGs). Methods. A retrospective analysis of patients with postoperative and recurrent HGGs treated in our hospital from April 1, 2018, to April 30, 2020. Patients should be treated by combination therapy (surgery + radiotherapy + chemotherapy). Patients who received apatinib combined with temozolomide chemotherapy were allocated to the research group (RG), while patients who received temozolomide chemotherapy alone were allocated to the control group (CG). The efficacy and toxic side effects were compared between the two groups. Results. There were 67 qualified patients retrieved, including 37 cases in the RG and 30 cases in the CG. There were no significant differences in objective remission rate (ORR) or disease control rate (DCR) between the control group and the study group ( P > 0.05 ). However, the overall improvement of clinical efficacy in the observation group was better than that in the control group ( P < 0.05 ). There was no significant difference in the incidence of adverse effects between the two groups ( P > 0.05 ). There were no significant differences in overall survival (OS) or progression-free survival (PFS) between the two groups ( P > 0.05 ). Conclusion. Low-dose apatinib combined with temozolomide and radiotherapy for HGGs is effective in improving efficacy, relieving brain edema, reducing the use of glucocorticoid drugs, and improving patients’ quality of life. It has mild adverse effects and is well tolerated by patients.

show abstract

Long Noncoding RNA SNHG16 Silencing Inhibits the Aggressiveness of Gastric Cancer via Upregulation of microRNA-628-3p and Consequent Decrease of NRP1 [Retraction]

Cited by 4 publications

References 0 publications

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism

Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas

Contact Info

Product

Resources

About